Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.
Today in one sentence: Two-month HIV shots kept the virus under control for two years; surgeons used AR glasses to see nerves during tumor surgery; a rare esophagus cancer gene change responded to a newer pill; a new RNA editor eased autism-like signs and lowered cholesterol in mice; and turning down a key switch in liver cells slowed scarring.
Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8
Personal shares from Christin here →
http://christin.substack.com/
Good news: Long‑acting HIV shots kept people’s virus under control for two years and were as effective as staying on daily pills. Most patients liked the shots more, which can make treatment easier to stick with.
Market readiness: 🙂🙂🙂🙂🙂 (already FDA‑approved in the U.S. as a two‑month injection; this trial strengthens confidence in real‑world use)
Good news: Surgeons used augmented‑reality (AR) glasses that project a patient’s 3D MRI onto the body during nerve‑tumor surgery. It helped them see critical nerves and vessels better and shortened operating time in a small clinical series.
Market readiness: 🙂🙂 (uses off‑the‑shelf AR hardware but evidence is from a 12‑patient study; needs larger trials before routine U.S. adoption)
Good news: A patient with metastatic esophageal cancer carrying a rare EGFR p.S768I mutation had a striking response to a third‑generation EGFR pill, suggesting a potential option when standard care fails.
Market readiness: 🙂🙂 (clinical drug exists but this specific medicine isn’t FDA‑approved in the U.S.; single‑patient evidence that warrants further study)
Good news: Scientists built a better RNA‑editing tool and showed it can fix disease‑related messages in live mice—lowering cholesterol and easing autism‑like behaviors. It points toward new one‑time treatments for genetic diseases.
Effective in vivo RNA base editing via engineered cytidine deaminase APOBECs fused with PUF proteins
Market readiness: 🙂 (mouse proof‑of‑concept; years away from human trials and U.S. availability)
Good news: Dialing down ETS1—a switch that activates scar‑forming liver cells—reduced fibrosis in experimental models, opening a new path to treat liver scarring that drives many liver diseases.
Market readiness: 🙂 (early lab/animal work; drug development would be at the starting line)
Thank you for taking the time to take care of yourself and your loved ones.
